Serine protease molecules and therapies

Patent metadata

Field	Value
Publication number	US-10920211-B2
Application number	US-201916575715-A
Country	US
Kind code	B2
Filing date	Sep 19, 2019
Priority date	Oct 4, 2012
Publication date	Feb 16, 2021
Grant date	Feb 16, 2021

Abstract

Cell-targeted serine protease constructs are provided. Such constructs can be used in methods for targeted cell killing such as for treatment cell of proliferative diseases (e.g., cancer). In some aspects, recombinant serine proteases, such as Granzyme B polypeptides, are provided that exhibit improved stability and cell toxicity. Methods and compositions for treating lapatinib or trastuzumab-resistant cancers are also provided.

First claim

What is claimed is:

1. A cell-targeting polypeptide construct comprising, from N- to C-terminus:
(a) a truncated serine protease having an IIGG, IVGG or ILGG at its N -terminus, the truncated serine protease having an amino acid sequence at least 95% identical to a SEQ ID NO: 1, SEQ ID NO: 46, SEQ ID NO:47, SEQ ID NO: 48, SEQ ID NO:49, SEQ ID NO: 50, SEQ ID NO: 51, SEQ ID NO: 52, SEQ ID NO: 53, SE q ID NO: 54, SEQ ID NO: 55, SEQ ID NO: 56, SEQ ID NO: 57 or SEQ ID NO: 58;
(b) an antibody heavy chain constant (Fc) domain; and
(c) a cell-targeting hormone domain.

2. The cell-targeting construct of claim 1 , wherein the cell-targeting hormone domain is human chorionic gonadotropin, gonadotropin releasing hormone, an androgen, an estrogen, thyroid-stimulating hormone, follicle-stimulating hormone, luteinizing hormone, prolactin, growth hormone, adrenocorticotropic hormone, antidiuretic hormone, oxytocin, thyrotropin-releasing hormone, growth hormone releasing hormone, corticotropin releasing hormone, somatostatin, dopamine, melatonin, thyroxine, calcitonin, parathyroid hormone, glucocorticoids, mineralocorticoids, adrenaline, noradrenaline, progesterone, insulin, glucagon, amylin, erythropoietin, calcitriol, calciferol, atrial-natriuretic peptide, gastrin, secretin, cholecystokinin, neuropeptide Y, ghrelin, PYY3-36, insulin-like growth factor-1, leptin, thrombopoietin or angiotensinogen.

3. The cell-targeting construct of claim 2 , wherein the cell-targeting hormone domain is chorionic gonadotropin or gonadotropin releasing hormone.

4. The cell-targeting construct of claim 1 , wherein the truncated granzyme polypeptide is 95% identical to a truncated serine protease selected from the group consisting of granzyme B (SEQ ID NO: 1), granzyme A (SEQ ID NO: 46), granzyme H (SEQ ID NO: 47), granzyme K (SEQ ID NO: 48), granzyme M (SEQ ID NO: 49).

5. The cell-targeting construct of claim 4 , wherein the truncated serine protease is 95% identical to Granzyme B (GrB) polypeptide (SEQ ID NO: 1).

6. The cell-targeting construct of claim 5 , wherein the truncated granzyme polypeptide comprises the sequence of SEQ ID NO:1.

7. The cell-targeting construct of claim 5 , wherein the GrB polypeptide comprises an amino acid substitution or deletion at the position corresponding to Cys 210.

8. The cell-targeting construct of claim 1 , further comprising a linker sequence between the truncated serine protease and the antibody heavy chain Fc domain and/or between the antibody heavy chain Fc domain and the cell-targeting hormone domain.

9. The cell-targeting construct of claim 8 , wherein the linker sequence is a protease-cleavable linker.

10. The cell-targeting construct of claim 1 , wherein the Fc domain is a human IgG Fc domain.

11. The cell-targeting construct of claim 10 , wherein the Fc domain is a human IgG 1 Fc domain.

Assignees

• Res Found Dev

Inventors

• Rosenblum Michael G
• Mohamedali Khalid Amanali
• Cheung Lawrence H

Classifications

• C07K2319/10

  containing a tag for extracellular membrane crossing, e.g. TAT or VP22 · CPC title

• C07K2319/01

  containing a localisation/targetting motif · CPC title

• C12N9/6424

  Serine endopeptidases (3.4.21) · CPC title

• C07K14/001

  by chemical synthesis · CPC title

• A61P19/08

  for bone diseases, e.g. rachitism, Paget's disease · CPC title